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1
CYTOTOXIC T LYMPHOCYTE THERAPY FOR THE TREATMENT AND
PREVENTION OF ADENOVIRUS INFECTION AFTER STEM CELL TRANS-
PLANT
Bollard, C.M.1, Myers, G.D.1, Weiss, H.1, Gee, A.P.1, Leung, K.1,
Krance, R.A.1, Brenner, M.K.1, Rooney, C.M.1, Heslop, H.E.1,
Leen, A.M.1 1Baylor College of Medicine, Houston, TX.
Adenoviruses (Adv) remain amajor cause of mortality andmorbidity
in hematopoietic stem cell transplant (SCT) recipients. We evaluated
the use of Adv-speciﬁc cytotoxic T lymphocytes (CTL) for prophy-
laxis and treatment of Adv infections post SCT. CTLs were initiated
by infecting donor-derived mononuclear cells with the Ad5f35 vector
(MOI 200 virus particles/cell). Responder cells were expanded by
weekly restimulation with autologous EBV-transformed B lympho-
blastoid cell lines (LCL) transduced with Ad5f35 at MOI of 500. 9 of
11 CTL lines manufactured for clinical use were predominantly
CD4

(range 12-95%), but all had a CD8 component (range 3.5-
79%). All CTL lines showed speciﬁc killing of Adv and EBV antigen-
bearing target cells. Recognition of Adv and EBV targets was not
signiﬁcantly different; at 20:1 effector:target ratio there was
18.514% speciﬁc lysis of Adv targets and 2315% lysis of EBV
targets while uninfected recipient target cells were not lysed
(1.52%). Hexon was the immunodominant Adv antigen in all CTL
lines. To test the hypothesis that polyclonal hexon-speciﬁc T cells can
provide protection against Adv infections in SCT recipients, we ad-
ministered donor-derived bi-virus-speciﬁc CTL lines to pediatric
recipients after allogeneic SCT. We have treated 7 patients in this
phase I dose escalation study; 2 patients on DL1 (5106/m2), 2 on
DL2 (1.5107/m2), 2 on DL3 (4.5107/m2). Of 6 patients who
received CTL as prophylaxis, all remain negative for Adv and EBV.
No adverse events attributable to CTL infusion. Increased EBV-
speciﬁc T cell frequency was detected in the peripheral blood (PB) by
4wks post infusion in all patients, likely due to the consistent presence
of this latent virus. However, there was no signiﬁcant rise in Adv-
speciﬁc T cell frequency post-infusion. The 7th patient received CTL
(5106/m2) as treatment for Adv disease. This patient had Adv pneu-
monia requiring ventilatory support. Post CTL the patient made a
dramatic clinical recovery, was weaned off mechanical ventilation, and
discharged a month after infusion. In contrast to the prophylaxis
group, this patient had a substantial rise in Adv-speciﬁc T cells in PB
by 4wks post CTL coinciding with clinical recovery and clearance of
Adv from the tracheal aspirate, suggesting that the infused cells were
effective in vivo. Adoptive immunotherapy for Adv appears safe but
expansion of Adv-speciﬁc CTL in vivo may require the presence of
antigen to stimulate the infused cells.
2
A DISTINCT PATTERN OF NON-HLA POLYMORPHISMS PREDICTS AN
INCREASED RISK FOR GvHD WITHOUT BENEFIT OF GvL IN HLA
MATCHED SIBLING TRANSPLANTS FOR CHRONIC MYELOID LEUKEMIA
(CML)
Dickinson, A.M.1, Pearce, K.F.1, Norden, J.1, Neylor, A.1, Holler, E.2,
Rocha, V.2, Gluckman, E.2, Kolb, H.J.2, Hromadnikova, I.2,
Sedlacek, P.2, Niederwieser, D.3, Brand, P.3, Ruutu, T.3, Apperley, J.3,
Goulmy, E.3, Olavarria, E.3, de Witte, T.3, Gratwohl, A.3 1Haemato-
logical Sciences, Medical School, Newcastle University, Newcastle upon
Tyne, United Kingdom; 2on behalf of EUROBANK; 3on behalf of the
Chronic Leukemia Working Party (CLWP) of the EBMT.
Non-HLA polymorphisms have been shown to increase risk of
GVHD and to inﬂuence outcome of allogeneic hematopoietic stem
cell transplants (HSCT). In view of their discordant effects on GvHD
and GvL, their role in general remains to be deﬁned. We made use of
a homogeneous cohort of 291 CMLHLAmatched sibling transplants
with known clinical risk factors. They were typed for Non-HLA
polymorphisms by SNPs or microsatellites including cytokines (IL-
1Ra, IL-4, IL-6, IL-10, IFN, TNF, TNFR11), steroid hormone
receptors (VDR and ER) and NOD2/CARD15 mutations. Two
clinical models were generated for the statistical analysis and as a basis
for further development: (i) using the EBMT risk score as a single
variable on an ordinal scale or (ii) using the individual clinical factors
of the EBMT risk score as binary indicator variables. The generated
prognostic indices were used to model Kaplan-Meier functions based
on good, intermediate and poor prognostic risk scores. Absence of
TNFRII-196 R, i.e. down regulation of TNF in the recipient, absence
of IL-10 ATC/ACC, i.e. intermediate IL-10 production in the donor,
and presence of IL-1Ra (allele 2), i.e. down regulation of IL-1 in the
donor, were associated with increased risk of chronic GvHD and poor
outcome in univariate analysis. After variable selection for EBMT risk
score, and integrating the three genotypes to themodel, the combined
effect of Recipient TNFRII-196 R, Donor IL-10 ATC/ACC and
Donor IL-1Ra (allele 2) signiﬁcantly improved the predictive value.
The Goodness of Fit of the models was assessed by Kaplan-Meier
curves, which showed signiﬁcant differences between the good versus
intermediate and poor prognosis groups (p 0.0012; 0.0000 and 0.02
respectively). The presence of any NOD2/CARD15 mutation
showed a trend for increased GvHD severity in patients with ad-
vanced disease stage. The worst prognostic scores always included the
absence of ATA/ACC in the donor and was evidenced in the steep
change in survival probability. This study suggests that distinct high
risk patterns of Non-HLA polymorphisms of patients and donors can
be deﬁned. This pattern inﬂuences survival due to factors which may
be associated with an increased risk of GvHD without the potential
beneﬁt of increased GvL response. Data add to the growing list of
situations where an unrelated donor might be preferred choice com-
pared to a high risk sibling donor. Non-HLA polymorphisms should
be integrated into the donor selection algorithms.
3
WT1-SPECIFIC T LYMPHOCYTES PARTICIPATE IN THE ELIMINATION
OF ACUTE LYMPHOBLASTIC LEUKEMIA FOLLOWING ALLOGENEIC
STEM CELL TRANSPLANTATION
Rezvani, K.1, Yong, A.S.M.1, Price, D.A.1, Mielke, S.1, Savani, B.1,
Gostick, E.2, Douek, D.1, Barrett, A.J.1 1National Institutes of Health,
Bethesda, MD; 2Nufﬁeld Department of Medicine, Oxford, United
Kingdom.
There is evidence that a graft-versus-leukemia (GVL) effect
occurs following allogeneic stem cell transplantation (SCT) for
acute lymphoblastic leukemia (ALL). However, the GVL effect
is often accompanied by graft-versus-host-disease (GVHD) and
disease relapse remains a major contributor to treatment failure.
Wilms’ tumor gene (WT1) is overexpressed in 70-90% of cases
of ALL and has been identiﬁed as a minimal residual disease
(MRD) marker. Therefore WT1 is an attractive immunothera-
peutic target in ALL. We investigated whether CD8 T-cells
directed against an HLA-A*0201 restricted epitope of WT1
(WT126) occur in ALL patients during the early phase of
immune reconstitution post-SCT (days 30-180). We analyzed
CD8 T-cell responses against WT1 in 10 HLA-A*0201
ALL SCT recipients and their respective donors using WT1/
HLA-A*0201 tetrameric complexes and ﬂow cytometry for in-
tracellular IFN-gamma (IFN-). WT1 gene expression was de-
tected in 7 of 10 samples from patients pre-SCT (median 19
1
10-4; range 0-1882 10-4 WT1/ABL). WT1 gene expression
in PB samples pre-SCT strongly correlated with WT1CD8
T-cell responses post-SCT. Five of 7 patients with detectable
WT1 expression in PB pre-SCT developed WT1 T-cell re-
sponses post SCT compared with 0 of 3 in whom WT1 was
undetectable pre-SCT (P  0.02). To monitor kinetics of WT1
CD8 T-cell responses and disease regression after HLA-iden-
tical SCT, absolute WT1 speciﬁc CD8 T-cell numbers and
WT1 expression in PB were calculated for each sampling point
in all donor–patient pairs. WT1 speciﬁc CD8 T-cell emer-
gence was associated with a decrease in WT1 gene expression
suggesting a WT1-driven GVL effect. Similarly, loss of WT1
speciﬁc CD8 T-cell response was associated with reappear-
ance of WT1 gene transcripts, consistent with a molecular
relapse (P  0.001), further supporting the involvement of
WT1-speciﬁc CD8 T-cells in the GVL response. WT1-
tetramerCD8 T cells had a predominantly effector- memory
phenotype (CD45ROCD27-CD57) and produced IFN-.
These results provide evidence of spontaneous T-cell reactivity
against a leukemia antigen in ALL patients. Our results support
the immunogenicity of WT1 in ALL patients post-SCT and the
potential for WT1 vaccines to boost GVL after SCT for ALL.
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